Hyderabad-based Transgene Biotek is in discussions with global pharma companies for a possible collaboration. The company has invested about Rs 150 crore in R&D facilities for drug development.
The company hopes to sign the deal in the next six months, according to KK Rao, chairman and managing director. “The two recent animal studies on our oral insulin project have yielded exceptional results, which gives us the confidence for the strategic partnership with a large pharma company,” he said on Tuesday.
The company last week said Mauritius-based Stream Value Fund had agreed to support its drug discovery in return for equity participation on a long-term basis.
The company has also decided to delist from the stock exchanges, according to Rao.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app